UCB at MDS 2019: Our proud mission to help patients with PSP
Posted byAlexander Klein, Patient Value Unit Neurology
Progressive supranuclear palsy (PSP) is a rare, seriously debilitating neurodegenerative brain disorder, marked by severe motor and cognitive symptoms such as balance and walking, speech, swallowing, vision, mood, behaviour and thinking.
As the name suggests, people with PSP often suffer rapid disease progression, having a life expectancy of approximately 6–8 years from symptom onset. The condition is characterised by a loss of brain cells, thought to be due to an accumulation of a misfolded protein called “tau”. Importantly, there is no known cure available for PSP, and no treatments to slow down, halt, or reverse the inevitable cognitive-motor decline experienced. The only available treatment options for patients are to help to manage symptoms.
Given the urgent need to provide hope for individuals living with PSP, UCB is extremely proud to be participating in the International Congress of Parkinson’s Disease and Movement Disorders (#MDSCONGRESS), September 22-26, 2019 in Nice, France.
Building on our long-standing heritage in Parkinson’s disease, the meeting provides us with a unique opportunity to engage with the global movement disorder community, to learn more about their needs, perspectives and experiences, and to reinforce our commitment to progressing treatment solutions for people living with movement disorders, including Parkinson's disease and PSP.
The UCB Tau Mission team will also be hosting a medical exhibition throughout the congress, providing insights into lived PSP patient experiences and sharing information from patient organisations around the world.
To find out more about PSP, click here
Read more about anti-tau antibodies in neurodegenerative diseases here.